QMSR Transition Guide: How Medical Device Manufacturers Are Adapting to FDA Part 820 Changes

What Is the QMSR and Why It Matters Now

The Quality Management System Regulation (QMSR) represents the most significant change to FDA's medical device quality system requirements in nearly three decades. Finalized in January 2025, the QMSR replaces the legacy 21 CFR Part 820 Current Good Manufacturing Practice (CGMP) requirements by incorporating ISO 13485:2016 by reference.

For medical device manufacturers, this is not a minor regulatory update. It fundamentally changes how FDA expects you to structure, document, and maintain your quality management system. The old Part 820, which has been the backbone of device manufacturing quality since 1996, is being retired in favor of a globally harmonized approach.

The rationale is straightforward: most device manufacturers already maintain ISO 13485 certification for international market access. Maintaining two parallel quality systems — one for FDA and one for ISO — creates redundancy, increases documentation burden, and introduces gaps where requirements diverge. The QMSR eliminates this duplication by aligning FDA requirements directly with the international standard.

But alignment does not mean simplification. The QMSR retains several FDA-specific requirements that go beyond ISO 13485, and manufacturers who assume a simple one-to-one mapping will find themselves out of compliance.

Key Changes from Part 820 to QMSR

Understanding what actually changed is critical before you begin your transition. Here are the most significant shifts:

ISO 13485:2016 as the baseline. The QMSR incorporates ISO 13485:2016 by reference, making it the primary quality system standard. Your QMS documentation must now explicitly align with ISO 13485 clause structure and terminology.

Retained FDA-specific requirements. Several Part 820 requirements have no equivalent in ISO 13485 and are retained in the QMSR. These include requirements for complaint handling (specifically MDR-reportable events), corrections and removals, unique device identification (UDI), and certain records retention requirements. Manufacturers must layer these requirements on top of their ISO 13485 system.

Design controls language alignment. While ISO 13485 Clause 7.3 covers design and development, the QMSR aligns design control terminology more closely with the international standard. However, FDA expectations around design verification, design validation, and design transfer remain rigorous. Do not interpret harmonization as relaxation.

Management responsibility updates. The QMSR adopts ISO 13485's management review framework, which requires more structured top-management involvement than the old Part 820. Quality policy, quality objectives, and management review outputs need documented evidence of executive engagement.

Supplier and purchasing controls. ISO 13485 Clause 7.4 requirements for purchasing are more prescriptive than old Part 820 purchasing controls. You will need to demonstrate supplier evaluation criteria, approved supplier lists with documented rationale, and re-evaluation schedules.

Document and record control harmonization. The distinction between documents and records is more clearly delineated under ISO 13485 than it was under Part 820. Your document control procedures must explicitly address both categories with appropriate controls for each.

QMSR Transition Timeline

The FDA has established a transition period to give manufacturers time to adapt. Here are the key dates every quality team should have on their calendar:

February 2, 2026: The QMSR becomes effective. From this date forward, new device submissions should reference QMSR compliance rather than Part 820 compliance.

February 2, 2027: Full compliance required. All manufacturers must have completed their transition to the QMSR framework. FDA will begin conducting inspections against QMSR requirements rather than legacy Part 820 requirements.

This two-year window (from the final rule publication) sounds generous, but manufacturers who have been through quality system overhauls know how quickly that time disappears. Between gap assessments, procedure rewrites, training, internal audits, and management reviews, most organizations need 12 to 18 months for a thorough transition.

If you have not started your transition by mid-2026, you are already behind schedule.

5-Step QMSR Transition Process

Based on successful transitions we have observed across the industry, here is a practical five-step approach:

Step 1: Gap Analysis Against ISO 13485:2016 + QMSR Addenda

Start with a clause-by-clause comparison of your current QMS against ISO 13485:2016 requirements plus the FDA-specific additions retained in the QMSR. This is not a checkbox exercise. For each clause, document your current state, identify gaps, and estimate the effort required to close them.

Pay particular attention to areas where Part 820 and ISO 13485 requirements diverge. For example, Part 820's Design History File (DHF) concept does not map cleanly to ISO 13485's design and development file requirements. Your gap analysis should identify these nuances.

The output of this step should be a prioritized action plan with owners and deadlines.

Step 2: Update Your Quality Manual and QMS Architecture

Your quality manual should be restructured to follow the ISO 13485 clause structure while incorporating QMSR-specific requirements. This is not about simply renaming sections — it requires rethinking how your quality system documentation hierarchy works.

Consider adopting a tiered documentation structure: Quality Manual (Tier 1) → Standard Operating Procedures (Tier 2) → Work Instructions and Forms (Tier 3) → Records and Evidence (Tier 4). This structure aligns with ISO 13485 expectations and makes audit navigation straightforward.

Update your scope statement, exclusions justification, and process interaction descriptions to reflect ISO 13485 language.

Step 3: Revise Procedures and Work Instructions

This is where the bulk of the work happens. Each SOP needs to be reviewed against the corresponding ISO 13485 clause and updated to reflect the harmonized requirements.

Focus areas that typically require the most revision: management review procedures, design and development procedures, purchasing and supplier management procedures, production and service provision procedures, and monitoring and measurement procedures.

For each procedure, ensure that the terminology aligns with ISO 13485, required records are explicitly identified, process owners are designated, and interaction with related processes is documented.

Step 4: Train Your Organization

A quality system transition that lives only in documents is a failed transition. Every person who interacts with the QMS needs to understand what changed and why.

Develop role-specific training plans. Your quality engineers need deep training on the new requirements and documentation structure. Production staff need to understand changes to work instructions and record-keeping. Management needs to understand their expanded responsibilities under ISO 13485's management review requirements.

Document all training with competency assessments — not just attendance records. ISO 13485 requires evidence of effectiveness of training, not just evidence that training occurred.

Step 5: Internal Audit and Management Review Against QMSR Requirements

Before the compliance deadline, conduct at least one full internal audit cycle against the QMSR requirements. This is your opportunity to identify remaining gaps before FDA inspectors find them.

Use auditors who are trained in both ISO 13485 and FDA-specific requirements. Consider engaging external auditors for an objective assessment.

Follow the internal audit with a comprehensive management review that evaluates the transition's effectiveness, identifies residual risks, and establishes ongoing monitoring plans.

Common QMSR Transition Mistakes

Having observed numerous transition efforts, these are the mistakes that derail manufacturers most frequently:

Treating it as a relabeling exercise. Simply changing "Part 820" to "QMSR" in your existing documents does not constitute compliance. FDA expects substantive alignment with ISO 13485, not cosmetic changes.

Forgetting FDA-specific requirements. The QMSR is not purely ISO 13485. Manufacturers who strip out FDA-specific complaint handling, MDR reporting, or UDI requirements in an effort to "simplify" will find themselves non-compliant.

Underestimating the documentation effort. A thorough gap analysis typically reveals 40 to 60 procedures that need revision. At 2 to 4 weeks per procedure (including review, approval, and training), this is 18 to 24 months of work for most organizations.

Skipping the training component. Updated procedures are useless if staff continue operating under the old system. Training must be comprehensive, role-specific, and documented with competency evidence.

Not involving suppliers. If your suppliers are providing components or services that affect product quality, their quality systems need to align with your updated requirements. Supplier communication and re-evaluation should begin early in the transition.

Waiting for FDA guidance. While FDA has published some guidance documents, manufacturers should not delay their transition waiting for additional clarification. The standard is published, the timeline is set, and the expectations are clear enough to begin work immediately.

Resources for Your QMSR Transition

Successfully navigating the QMSR transition requires the right tools, templates, and expertise. Here are the resources that matter most:

ISO 13485:2016 standard. If you do not already have the current version, purchase it directly from ISO or your national standards body. This is now your primary reference document.

FDA QMSR final rule and preamble. The preamble to the final rule contains extensive discussion of FDA's intent and interpretation of specific requirements. It is essential reading for quality professionals.

FDA guidance documents. Monitor FDA's guidance page for QMSR-specific guidance. Several draft guidances are expected in 2026.

Industry associations. Organizations like RAPS, AAMI, and MDMA are publishing transition resources and hosting training events.

The manufacturers who transition earliest gain a competitive advantage: they can market QMSR compliance to customers, reduce audit findings, and avoid the rush of last-minute transitions that typically strain registrar availability.